In the fourth quarter of 2025, Bretton Fund, an investment management firm, disclosed its strategic decision to divest from Revvity, Inc. (RVTY). This move was detailed in their investor letter for the period, which also highlighted the fund's overall performance. While the market grappled with varying sentiments regarding a potential AI bubble, Bretton Fund maintained its long-term investment philosophy, choosing to reduce exposure to more speculative ventures. The firm's investment in Revvity concluded with a significant loss, underscoring the complexities and risks inherent in the health sciences sector, particularly in an environment of shifting market dynamics and strategic missteps by company management.
Bretton Fund's Strategic Divestment from Revvity Amidst Market Shifts
In the fourth quarter of 2025, Bretton Fund, a prominent investment management entity, formally announced its departure from its investment in Revvity, Inc. (NYSE:RVTY). This decision was elaborated upon in the fund's investor letter, which also reported a 1.44% return for the quarter, in contrast to the S&P 500 Index's 2.66%. For the entirety of 2025, the Fund recorded an 11.58% return, trailing the Index's 17.88%. The investment in Revvity, a company specializing in health sciences solutions and technologies, ultimately resulted in a substantial 28.5% loss for Bretton Fund, translating to an internal rate of return of -5.90%.
The fund's initial investment in the former PerkinElmer, later known as Revvity, was driven by optimism surrounding a "new golden age for medicine," characterized by advancements in biologics, personalized medicine, AI-driven therapies, and mRNA technology. Revvity, with its focus on consumables for research facilities and customer-facing diagnostics, was initially perceived as a robust platform to capitalize on these trends. However, Bretton Fund noted that management's allocation of COVID-19 testing profits towards what they deemed "overpriced acquisitions" and the divestiture of its profitable food testing division proved detrimental. Further compounding these issues were a slowdown in pharmaceutical research spending and a significant reduction in science funding by the FDA, leaving Revvity in a precarious position.
As of March 4, 2026, Revvity, Inc. (NYSE:RVTY) shares closed at $98.49, experiencing a one-month decline of 1.03% and a 52-week loss of 13.00%. The company maintains a market capitalization of $11.166 billion. While Revvity was held by 35 hedge fund portfolios at the end of Q4 2025, an increase from 22 in the preceding quarter, Bretton Fund's move highlights a cautious approach towards certain segments of the market. The fund, while acknowledging the potential of Revvity, expressed a preference for AI stocks that offer greater upside potential with reduced downside risk, particularly those benefiting from current economic trends such as Trump-era tariffs and the reshoring of manufacturing.
This strategic exit by Bretton Fund serves as a powerful reminder for investors about the perpetual challenge of navigating dynamic market conditions and the critical importance of scrutinizing management decisions within portfolio companies. The insights shared in their letter underscore that even within a promising sector like health sciences, unforeseen shifts in research funding and acquisition strategies can profoundly impact investment outcomes. It reinforces the necessity of adapting investment theses and being prepared to divest when core assumptions about a company's growth trajectory or management effectiveness no longer hold true.